EaveTubes for Vector Control
Malaria
About this trial
This is an interventional prevention trial for Malaria focused on measuring EaveTubes, Housing, Malaria control, LLINs, Cost-effectiveness, Malaria, Vector-borne diseases, Mosquito vectors, Incidence
Eligibility Criteria
Village Level Inclusion Criteria: ≥ 80% of Households (HHs) must be suitable for EaveTube(ET) installation. ≥70% of HHs willing to have ETs installed. No participation in the previous Screening + ETs cluster randomized control trial (cRCT). Received standard pyrethroid-only long lasting insecticide nets(LLINs) (Permanet 2.0). 100-300 HHs per village. ≥2 km apart from another village. Village Level Exclusion Criteria: < 80% of HHs suitable for ET installation. <70% of HHs willing to have ETs installed. Villages being treated by indoor residual spray (IRS) and/or new generation bed net campaigns. Participation in previous Screening + ET cRCT. <100 and >300 households per village. <2 km from another village. Household Level Inclusion Criteria HHs must be suitable for ET installation. Provision of consent from heads of HH. Household Level Exclusion Criteria HH not suitable for ET installation (e.g. houses with poor quality thatch roofing or very large eaves or wall gaps, houses in substantial disrepair, unfinished houses under construction, poorly constructed houses, ). No provision of consent from heads of HH. Individual Level Inclusion Criteria Children aged ≥ 6 months to < 8 years old at time of enrollment (so all participants are under 10 years old for the duration of clinical follow-up). Provision of written, informed consent by parents/care givers. Children must reside in villages enrolled in the study and in ETs-treated HHs. Hemoglobin at baseline of >7 mg/dL. Individual Level Exclusion Criteria Children aged < 6 months or ≥ 8 years old at time of enrollment. No provision of written, informed consent by parents/care givers for child participation. Expected to be non-resident during a significant part of the transmission season. Hemoglobin at baseline of ≤7 mg/dL, have a known chronic disease, or who have signs of clinical decompensation. Participation in another clinical trial investigating a drug, vaccine, medical device or procedure.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
In2Care EaveTube
Control
EaveTube installation with deltamethrin treated netting; in addition to standard of care (standard pyrethroid-only bednets)
Standard of care (standard pyrethroid-only bednets)